-+ 0.00%
-+ 0.00%
-+ 0.00%

Belite Bio's Tinlarebant Receives Orphan Drug Status From Swiss Agency For Therapeutic Products To Treat Stargardt Disease

Benzinga·05/18/2026 20:02:05
Listen to the news

Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted tinlarebant, the Company's lead product candidate, orphan drug status (ODS) for the treatment of Stargardt disease (STGD1), a rare, inherited retinal disorder caused by mutations in the ABCA4 gene.